Grifols SG&A Expense Quarterly:
170.80M for March 31, 2013Grifols Historical SG&A Expense Quarterly Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 170.80M |
| Dec. 31, 2012 | 193.49M |
| Sept. 30, 2012 | 168.69M |
| June 30, 2012 | 169.97M |
| March 31, 2012 | 175.46M |
| Dec. 31, 2011 | 195.11M |
| Sept. 30, 2011 | 164.64M |
| June 30, 2011 | 188.56M |
| March 31, 2011 | 78.63M |
| Dec. 31, 2010 | 72.90M |
| Sept. 30, 2010 | -117.25M |
About SG&A Expense
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
Learn More
GRFS SG&A Expense Quarterly Benchmarks
| Companies | |
|---|---|
| Cadence Pharmaceuticals | 21.64M |
| Gilead Sciences | 374.30M |
| ARCA biopharma | 0.648M |
GRFS SG&A Expense Quarterly Rankings
| Overall |
90th percentile 725 of 8007 |
| Sector |
89th percentile 74 of 685 in Healthcare |
| Industry |
97th percentile 7 of 248 in Biotechnology |
GRFS SG&A Expense Quarterly Range, Past 5 Years
| Minimum | -117.25M | Sep 2010 |
| Maximum | 195.11M | Dec 2011 |
| Average | 132.82M |
